dicholesteryl carbonate | 29331-39-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: dicholesteryl carbonate
• 英文别名: DCC；Kohlensaeure-dicholesterylester；Dicholesteryl-carbonat；Cholesteryl carbonate；bis[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] carbonate
• CAS: 29331-39-3
• 化学式: C₅₅H₉₀O₃
• 分子量: 799.318
• InChiKey: JWXLCQHWBFHMOI-NIQMUPOESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  18.5
• 重原子数：
  58
• 可旋转键数：
  14
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  胆固醇甲酰氯 在 吡啶 、 苯 作用下， 生成 dicholesteryl carbonate
  参考文献：
  名称：

  Kondensationen von Chlorameisens�urecholesterylester mit Alkoholen und Phenolen

  摘要：

  DOI：

  10.1007/bf01522071

文献信息

• Sustainded-release composition including amorphous polymer
  申请人：University Technology Corporation

  公开号：US20020132007A1

  公开（公告）日：2002-09-19

  Provided is a sustained release composition for sustained release of a pharmaceutical substance. The composition includes a biocompatible polymer that is highly amorphous and a pharmaceutical substance in a hydrophobic ion complex with an amphiphilic material. Also provided a compressed antisolvent method for manufacturing the composition, various product forms incorporating the composition and various uses for the composition.

  提供了一种用于缓慢释放药物物质的缓慢释放组合物。该组合物包括一种高度非晶态的生物相容性聚合物和一种与一种两性物质形成疏水离子复合物的药物物质。还提供了一种压缩反溶剂法制造该组合物的方法，包括该组合物的各种产品形式以及该组合物的各种用途。
• [EN] RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS<br/>[FR] LIPIDES CATIONIQUES LIBÉRABLES POUR SYSTÈMES D'ADMINISTRATION D'ACIDES NUCLÉIQUES
  申请人：ENZON PHARMACEUTICALS INC

  公开号：WO2010057155A1

  公开（公告）日：2010-05-20

  The present invention is directed to releasable cationic lipids and nanoparticle compositions for the delivery of nucleic acids and methods of modulating an expression of a target gene using the same. In particular, the invention relates to cationic lipids including an acid labile linker, and nanoparticle compositions containing the same.

  本发明涉及可释放的阳离子脂质和纳米颗粒组合物，用于传递核酸并利用其调节靶基因的表达的方法。具体而言，本发明涉及包含酸敏感连接剂的阳离子脂质和含有该连接剂的纳米颗粒组合物。
• Physicochemical Properties and Antifungal Activity of Amphotericin B Incorporated in Cholesteryl Carbonate Esters
  作者：Rabkwan Chuealee、Timothy Scott Wiedmann、Teerapol Srichana

  DOI：10.1002/jps.22398

  日期：2011.5

  The antifungal activity of amphotericin B (AmB) incorporated in three cholesteryl carbonate esters (CCEs), sodium cholesteryl carbonate, cholesteryl palmityl carbonate, and dicholesteryl carbonate, was examined to assess their potential for use in a dry powder aerosol. Formulations containing dissolved AmB were stable for 6 months. The particle size varied inversely with liquid crystalline content

  研究了掺入三种胆固醇碳酸酯（CCE），碳酸胆固醇酯，碳酸胆固醇酯棕榈酸酯和碳酸二胆固醇酯中的两性霉素B（AmB）的抗真菌活性，以评估其在干粉气雾剂中的潜力。含有溶解的AmB的制剂可稳定放置6个月。粒径与液晶含量成反比，观察到的质量中值空气动力学直径为4至8μm。这与液晶的视觉外观一致，因为液晶的密度低并且在室温下自由流动。当分散在水中时，CCE的存在降低了AmB释放的速率和程度，与估计的液晶/水分配系数一致。尽管如此，生物活性研究表明，AmB的释放速率始终足以杀死真菌。用CCE制成干粉的AmB似乎有望用于治疗肺部真菌感染。
• BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM
  申请人：Zhao Hong

  公开号：US20110305769A1

  公开（公告）日：2011-12-15

  The present invention is directed to cationic lipid for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to cholesterol and its derivatives having multiple positively charged moieties via branching spacers, and nanoparticle compositions of oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid and a PEG lipid.

  本发明涉及用于递送寡核苷酸的阳离子脂质以及利用纳米粒子组合物调节靶向基因表达的方法。具体而言，本发明涉及通过分支间隔物具有多个带正电性的衍生物的胆固醇及其衍生物，以及封装在阳离子脂质、融合脂质和PEG脂质混合物中的寡核苷酸纳米粒子组合物。
• Biocompatible cationic detergents and uses therefor
  申请人：University Technology Corporation

  公开号：US20020032166A1

  公开（公告）日：2002-03-14

  Provided is a method for preparing a true, homogeneous solution of a pharmaceutical substance dissolved in an organic solvent in which the pharmaceutical substance is not normally soluble. Solubilization is obtained by forming a hydrophobic ion pair complex involving the pharmaceutical substance and an amphiphilic material. The resulting organic solution may be further processed to prepare pharmaceutical powders. A biodegradable polymer may be co-dissolved with the pharmaceutical substance and the amphiphilic material and may be incorporated into a pharmaceutical powder. A preferred method for preparing pharmaceutical powders is to subject the organic solution to gas antisolvent precipitation using a supercritical gas antisolvent such as carbon dioxide. Also provided is a method for making hollow particles having a fiber-like shape which would provide enhanced retention time in the stomach if ingested by a human or animal host. Further provided are novel biocompatible cationic surfactants and uses therefor, including the delivery, in vitro and in vivo, of nucleic acids into cells to transform the cells.

  提供了一种制备药物物质在有机溶剂中真正均质溶解的方法，其中药物物质通常不溶于有机溶剂。通过形成涉及药物物质和两性分子材料的疏水离子对复合物来获得溶解度。所得到的有机溶液可以进一步处理以制备药物粉末。生物可降解聚合物可以与药物物质和两性分子材料共溶，并可以并入药物粉末中。制备药物粉末的首选方法是将有机溶液经过超临界气体反溶剂沉淀使用超临界气体反溶剂如二氧化碳。此外，提供了一种制备纤维状空心粒子的方法，如果被人类或动物宿主吞咽，将提供增强的胃滞留时间。还提供了新型生物相容阳离子表面活性剂及其用途，包括将核酸在体外和体内传递到细胞中以转化细胞。